14 results on '"Toyama, Hirochika"'
Search Results
2. Novel concept of “sequential particle radiotherapy” with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus
- Author
-
Komatsu, Shohei, Terashima, Kazuki, Ishihara, Nobuaki, Matsuo, Yoshiro, Kido, Masahiro, Yanagimoto, Hiroaki, Toyama, Hirochika, Tokumaru, Sunao, Okimoto, Tomoaki, and Fukumoto, Takumi
- Published
- 2024
- Full Text
- View/download PDF
3. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma
- Author
-
Abe, Shohei, Masuda, Atsuhiro, Matsumoto, Tomonori, Inoue, Jun, Toyama, Hirochika, Sakai, Arata, Kobayashi, Takashi, Tanaka, Takeshi, Tsujimae, Masahiro, Yamakawa, Kohei, Gonda, Masanori, Masuda, Shigeto, Uemura, Hisahiro, Kohashi, Shinya, Inomata, Noriko, Nagao, Kae, Harada, Yoshiyuki, Miki, Mika, Irie, Yosuke, Juri, Noriko, Ko, Testuhisa, Yokotani, Yusuke, Oka, Yuki, Ota, Shogo, Kanzawa, Maki, Itoh, Tomoo, Imai, Toshio, Fukumoto, Takumi, Hara, Eiji, and Kodama, Yuzo
- Published
- 2024
- Full Text
- View/download PDF
4. Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma
- Author
-
Fujinaka, Ryosuke, Urade, Takeshi, Kido, Masahiro, Komatsu, Shohei, Gon, Hidetoshi, Fukushima, Kenji, Komatsu, Masato, Yanagimoto, Hiroaki, Toyama, Hirochika, and Fukumoto, Takumi
- Published
- 2024
- Full Text
- View/download PDF
5. Rim Enhancement on Contrast-Enhanced CT as a Predictor of Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
- Author
-
Yamaguchi, Takeru, Sofue, Keitaro, Ueshima, Eisuke, Sugiyama, Naoki, Yabe, Shinji, Ueno, Yoshiko, Masuda, Atsuhiro, Toyama, Hirochika, Kodama, Takayuki, Komatsu, Masato, Hori, Masatoshi, and Murakami, Takamichi
- Subjects
PANCREATIC duct ,PROGNOSIS ,OVERALL survival ,ADENOCARCINOMA ,PROGRESSION-free survival ,PANCREATIC intraepithelial neoplasia ,CONTRAST-enhanced magnetic resonance imaging - Abstract
This study investigated the utility of imaging features, such as rim enhancement on contrast-enhanced CT (CECT), in predicting the prognosis of pancreatic ductal adenocarcinoma (PDAC). This retrospective study included 158 patients (84 men; mean age, 68 years) with pathologically confirmed PDAC. The following imaging features were evaluated on CECT by two radiologists: tumor size, tumor attenuation, and the presence of rim enhancement. Cox proportional hazards analysis was performed to identify the imaging and clinicopathological features for predicting disease-free survival (DFS) and overall survival (OS). Pathological features were compared with the presence of rim enhancement. Among the 158 patients, 106 (67%) underwent curative surgery (surgery group) and 52 (33%) received conservative treatment (non-surgery group). Rim enhancement was observed more frequently in the non-surgery group than in the surgery group (44% vs. 20%; p < 0.001). Rim enhancement showed significant associations with shorter DFS and OS in the surgery group (hazard ratios (HRs), 3.03 and 2.99; p < 0.001 and p = 0.003, respectively), whereas tumor size showed significant associations with shorter OS (HR per 1 mm increase, 1.08; p < 0.001). PDACs with rim enhancement showed significant associations with higher histological tumor grades (p < 0.001). PDAC with rim enhancement on CECT could predict poorer prognosis and more aggressive tumor grades. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. A Novel Method Using Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetate Acid-Enhanced Magnetic Resonance Imaging for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients with a Major Portal Vein Tumor Thrombus.
- Author
-
Nishio, Kosuke, Komatsu, Shohei, Sofue, Keitaro, Kido, Masahiro, Kuramitsu, Kaori, Gon, Hidetoshi, Fukushima, Kenji, Urade, Takeshi, Yanagimoto, Hiroaki, Toyama, Hirochika, and Fukumoto, Takumi
- Subjects
PATIENT portals ,MAGNETIC resonance imaging ,PORTAL vein ,LIVER failure ,HEPATOCELLULAR carcinoma - Abstract
Introduction: The usefulness of gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging (EOB-MRI) in assessing the functional future remnant liver volume (fFRLV) to predict post-hepatectomy liver failure (PHLF) has been previously reported. Herein, we evaluated the efficacy of this technique in patients with hepatocellular carcinoma (HCC) with a major portal vein tumor thrombus (PVTT). Methods: This study included 21 patients with PVTT in the ipsilateral first-order branch (Vp3) and 30 patients with PVTT in the main trunk/contralateral branch (Vp4). To evaluate fFRLV, the signal intensity (SI) of the remnant liver was determined on T1-weighted images, using both conventional and newly developed methods. The fFRLV was calculated using the SI of the remnant liver and muscle, remnant liver volume, and body surface area. Preoperative factors predicting PHLF (≥grade B) in HCC patients with Vp3/4 PVTT were evaluated. Results: In the Vp3 group, we found fFRLV area under the receiver-operating characteristic curves (AUCs) above 0.70 (AUC = 0.875, 0.750) using EOB-MRI results calculated using either the plot or whole method. None of the parameters in the Vp4 group had an AUC greater than 0.70. Conclusion: The fFRLV calculated by EOB-MRI using the whole method can be as useful as the conventional method in predicting PHLF (≥grade B) for HCC patients with Vp3 PVTT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report.
- Author
-
Ishihara, Nobuaki, Komatsu, Shohei, Kido, Masahiro, Gon, Hidetoshi, Fukushima, Kenji, Urade, Takeshi, Yoshida, Toshihiko, Arai, Keisuke, Yanagimoto, Hiroaki, Toyama, Hirochika, and Fukumoto, Takumi
- Subjects
BILE ducts ,TYPE 1 diabetes ,DRUG side effects ,THROMBOSIS ,CANCER chemotherapy ,HEPATOCELLULAR carcinoma - Abstract
Tremelimumab plus durvalumab (Dur/Tre) is the first-line treatment for advanced hepatocellular carcinoma (HCC) worldwide. The present report describes the case of a 68-year-old man diagnosed with advanced HCC and a bile duct tumor thrombus (BDTT) who achieved a complete response to Dur/Tre therapy. The BDTT progressed to the bifurcation of the left and right hepatic ducts. Over time, both the tumors and BDTT progressively decreased in size, and a complete response was confirmed using the Response Evaluation Criteria in Solid Tumors (version 1.1.) 6 months after treatment administration. Subsequently, immune-related adverse events, including type 1 diabetes mellitus and diabetic ketoacidosis, emerged, leading to treatment discontinuation. The patient was undergoing outpatient follow-up in a drug-free state with no signs of recurrence 290 days after the initial administration of Dur/Tre. Although long-term and meticulous observations are required, the present findings could influence the choice of systemic chemotherapy for advanced HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Needle-tract seeding following endoscopic ultrasound-guided fine-needle aspiration using a 25G needle for pancreatic tail cancer.
- Author
-
Irie, Yosuke, Sakai, Arata, Kobayashi, Takashi, Masuda, Atsuhiro, Kanzawa, Maki, Toyama, Hirochika, and Kodama, Yuzo
- Published
- 2024
- Full Text
- View/download PDF
9. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
- Author
-
Yoshida, Michihiko, Yanagimoto, Hiroaki, Tsugawa, Daisuke, Akita, Masayuki, Urade, Takeshi, Nanno, Yoshihide, Fukushima, Kenji, Gon, Hidetoshi, Komatsu, Shohei, Asari, Sadaki, Kido, Masahiro, Toyama, Hirochika, Ajiki, Tetsuo, and Fukumoto, Takumi
- Subjects
- *
ADJUVANT chemotherapy , *PROPENSITY score matching , *RETROSPECTIVE studies , *OVERALL survival , *CHOLANGIOGRAPHY ,BILIARY tract cancer - Abstract
Introduction: Surgical resection is considered an effective cure for biliary tract cancer (BTC); however, the prognosis is unsatisfactory despite improved surgical techniques and perioperative management. The recurrence rate remains high even after curative resection. The efficacy of adjuvant chemotherapy in pancreatic and gastric cancers has been previously reported, and the feasibility of adjuvant therapy with S-1 has recently been reported in patients with resected BTC. We aimed to retrospectively investigate the effects of adjuvant chemotherapy with S-1 on resected advanced BTC. Methods: We included data from 438 BTC patients who underwent resection between 2001 and 2020. After excluding patients with pTis-pT1 (n = 112) and other exclusion criteria, 266 patients were included in the analysis. Results: After propensity score matching, 48 patients received S-1 adjuvant chemotherapy (S-1 group), and 48 patients received non-S1 adjuvant chemotherapy or underwent surgery alone (Non-S-1 group). The patients in the S-1 group had significantly better overall survival (OS) than those in the non-S-1 group (MST 51 vs 37 months, hazard ratio [HR]:.54, 95% confidence interval [CI]:.30-.98, P =.04). The S-1 group had a significantly better recurrence-free survival (RFS) than the non-S-1 group (94 vs 21 months, HR:.57, 95% CI:.33-.97, P =.03). Subgroup analyses for OS and RFS exhibited the benefits of S-1 in patients aged <75 years and in patients with primary sites of extrahepatic and perineural invasion and curability of R0. Discussion: S-1 adjuvant therapy is promising for improving the postoperative survival of patients with resected advanced BTC, positive nerve invasion, and R0 resection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
- Author
-
Ishihara, Nobuaki, Komatsu, Shohei, Sofue, Keitaro, Ueshima, Eisuke, Yano, Yoshihiko, Fujishima, Yoshimi, Ishida, Jun, Kido, Masahiro, Gon, Hidetoshi, Fukushima, Kenji, Urade, Takeshi, Yanagimoto, Hiroaki, Toyama, Hirochika, Ueda, Yoshihide, Kodama, Yuzo, Murakami, Takamichi, and Fukumoto, Takumi
- Abstract
Aim Methods Results Conclusions The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy.Ninety‐five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non‐simple nodular (non‐SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes.Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non‐SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non‐SN group (39.3% vs. 15.4%,
p = 0.012). Additionally, the median time to nodular progression was longer in the non‐SN group (21.0 months vs. 8.1 months,p = 0.119) compared to the SN group. Six patients with non‐SN lesions underwent sequential local therapy.Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non‐SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non‐SN lesions. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
11. Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study.
- Author
-
Gonda M, Masuda A, Kobayashi T, Iemoto T, Kakuyama S, Ezaki T, Ikegawa T, Hirata Y, Tsumura H, Ogisu K, Nakano R, Fujigaki S, Nakagawa T, Takagi M, Yamanaka K, Sato Y, Fujita K, Furumatsu K, Kato T, Sakai A, Shiomi H, Sanuki T, Arisaka Y, Okabe Y, Toyama H, Sofue K, and Kodama Y
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Time Factors, Early Detection of Cancer methods, Dilatation, Pathologic diagnostic imaging, Pancreas diagnostic imaging, Pancreas pathology, Adult, Aged, 80 and over, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms pathology, Pancreatic Neoplasms diagnosis, Carcinoma, Pancreatic Ductal diagnostic imaging, Carcinoma, Pancreatic Ductal pathology, Disease Progression, Tomography, X-Ray Computed, Pancreatic Ducts diagnostic imaging, Pancreatic Ducts pathology, Atrophy
- Abstract
Background: Focal parenchymal atrophy and main pancreatic duct (MPD) dilatation have been identified as early signs of pancreatic ductal adenocarcinoma. However, limited evidence exists regarding their temporal progression due to previous study limitations with restricted case numbers., Objective: To ascertain a more precise frequency assessment of suspicious pancreatic ductal adenocarcinoma findings as well as delineate the temporal progression of them., Methods: A multicenter retrospective study was conducted on patients diagnosed with pancreatic ductal adenocarcinoma between 2015 and 2021. We included patients who had undergone at least one computed tomography (CT) scan ≥6 months before diagnosing pancreatic ductal adenocarcinoma. The temporal progression of suspicious pancreatic ductal adenocarcinoma findings on CT was investigated., Results: Out of 1832 patients diagnosed with pancreatic ductal adenocarcinoma, 320 had a previous CT before their diagnosis. Suspicious pancreatic ductal adenocarcinoma findings were detected in 153 cases (47.8%), with focal parenchymal atrophy (26.6%) being the most common followed by MPD dilatation (11.3%). Focal parenchymal atrophy was the earliest detectable sign among all suspicious findings and became visible on average 2.7 years before diagnosis, and the next most common, MPD dilatation, 1.1 years before diagnosis. Other findings, such as retention cysts, were less frequent and appeared around 1 year before diagnosis. Focal parenchymal atrophy followed by MPD dilatation was observed in 10 patients but not in reverse order. Focal parenchymal atrophy was more frequently detected in the pancreatic body/tail. No significant relationship was found between the pathological pancreatic ductal adenocarcinoma differentiation or tumor stage and the time course of the CT findings. All cases of focal parenchymal atrophy progressed just prior to diagnosis, and the atrophic area was occupied by tumor at diagnosis. Main pancreatic duct dilatation continued to progress until diagnosis., Conclusion: This large-scale study revealed that the temporal progression of focal parenchymal atrophy is the earliest detectable sign indicating pancreatic ductal adenocarcinoma. These results provide crucial insights for early pancreatic ductal adenocarcinoma detection., (© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
12. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
- Author
-
Koizumi A, Komatsu S, Omiya S, Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, Urade T, So S, Yoshida T, Arai K, Fujinaka R, Shimura Y, Yanagimoto H, Toyama H, Ueda Y, Kodama Y, and Fukumoto T
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Phenylurea Compounds therapeutic use, Phenylurea Compounds administration & dosage, Aged, 80 and over, Antineoplastic Agents therapeutic use, Antineoplastic Agents administration & dosage, Treatment Outcome, Adult, Ramucirumab, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular pathology, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Quinolines therapeutic use, Quinolines administration & dosage, alpha-Fetoproteins metabolism
- Abstract
Background/aim: The treatment algorithm for systemic therapies for advanced hepatocellular carcinoma (HCC) has changed dramatically; however, the therapeutic landscape for sequential second-line or later-line treatments, including ramucirumab, remains controversial. This study aimed to investigate the role of ramucirumab for treating HCC., Patients and Methods: We retrospectively analyzed data from 17 patients with advanced HCC who received ramucirumab, and 8 of them who received lenvatinib re-administration after ramucirumab treatment failure., Results: The median overall survival of 17 patients treated with ramucirumab was 11.5 months. The median ratios of the 1-month post-treatment α-fetoprotein (AFP) levels and albumin-bilirubin (ALBI) scores to the pre-treatment AFP levels and ALBI scores following ramucirumab treatment were 0.880 and 0.965, respectively. The median ratios of the 1-month post-treatment AFP and ALBI levels to the pre-treatment levels were 1.587 and 0.970 for mALBI grade 1/2a, and 1.313 and 0.936 for mALBI grade 2b/3, respectively. Six of the eight patients who received lenvatinib rechallenge treatment exhibited a decrease in AFP levels one month post-lenvatinib treatment. Deterioration of liver function 3 months post-lenvatinib treatment was noted in five of the eight patients who received lenvatinib rechallenge treatment after ramucirumab., Conclusion: Ramucirumab may be equally useful in patients with unresectable HCC who have poor liver function or whose liver function is aggravated by other therapies. Rechallenge treatment with lenvatinib after ramucirumab may be a valid treatment option for HCC., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.
- Author
-
Gon H, Komatsu S, Omiya S, Kido M, Fukushima K, Urade T, Yoshida T, Arai K, Ishida J, Nanno Y, Tsugawa D, Yanagimoto H, Toyama H, and Fukumoto T
- Subjects
- Humans, Female, Male, Middle Aged, Prognosis, Aged, Retrospective Studies, Serum Albumin analysis, Serum Albumin metabolism, Adult, Biomarkers, Tumor blood, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular blood, Liver Neoplasms surgery, Liver Neoplasms pathology, Liver Neoplasms mortality, Liver Neoplasms blood, Bilirubin blood, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Neoplasm Recurrence, Local blood, Hepatectomy
- Abstract
Background/aim: This study aimed to evaluate the utility of the albumin-bilirubin grade for predicting the prognosis after repeat liver resection for patients with recurrent hepatocellular carcinoma., Patients and Methods: Ninety patients with intrahepatic recurrent hepatocellular carcinoma who underwent repeat liver resection at our institution between 2005 and 2019 were retrospectively analyzed. Cox proportional-hazards regression models evaluated independent preoperative prognostic factors, including the albumin-bilirubin grade. Prognosis differences between patients with albumin-bilirubin grades 1 and 2 were analyzed using the Kaplan-Meier method., Results: Cox proportional-hazards regression analysis revealed that albumin-bilirubin grade 2 (p=0.003) and early recurrence within one year from the initial surgery (p=0.001) were independently associated with poor recurrence-free survival, and albumin-bilirubin grade 2 (p=0.020) was independently associated with poor overall survival. The five-year recurrence-free (31% and 17%, respectively) and overall (86% and 60%, respectively) survival rates after repeat liver resection for patients with albumin-bilirubin grades 1 and 2 were significantly different between groups (both p=0.003)., Conclusion: The albumin-bilirubin grade is useful for preoperatively predicting favorable survival rates after repeat liver resection for patients with recurrent hepatocellular carcinoma. Patients with an albumin-bilirubin grade 1 are better candidates for surgical treatment of recurrent hepatocellular carcinoma., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Utility of plasma D-dimer for diagnosis of venous thromboembolism after hepatectomy.
- Author
-
Miyake T, Yanagimoto H, Tsugawa D, Akita M, Asakura R, Arai K, Yoshida T, So S, Ishida J, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Asari S, Toyama H, Kido M, Ajiki T, and Fukumoto T
- Abstract
Background: Venous thromboembolism (VTE) is a potentially fatal complication of hepatectomy. The use of postoperative prophylactic anticoagulation in patients who have undergone hepatectomy is controversial because of the risk of postoperative bleeding. Therefore, we hypothesized that monitoring plasma D-dimer could be useful in the early diagnosis of VTE after hepatectomy., Aim: To evaluate the utility of monitoring plasma D-dimer levels in the early diagnosis of VTE after hepatectomy., Methods: The medical records of patients who underwent hepatectomy at our institution between January 2017 and December 2020 were retrospectively analyzed. Patients were divided into two groups according to whether or not they developed VTE after hepatectomy, as diagnosed by contrast-enhanced computed tomography and/or ultrasonography of the lower extremities. Clinicopathological factors, including demographic data and perioperative D-dimer values, were compared between the two groups. Receiver operating characteristic curve analysis was performed to determine the D-dimer cutoff value. Univariate and multivariate analyses were performed using logistic regression analysis to identify significant predictors., Results: In total, 234 patients who underwent hepatectomy were, of whom (5.6%) were diagnosed with VTE following hepatectomy. A comparison between the two groups showed significant differences in operative time (529 vs 403 min, P = 0.0274) and blood loss (530 vs 138 mL, P = 0.0067). The D-dimer levels on postoperative days (POD) 1, 3, 5, 7 were significantly higher in the VTE group than in the non-VTE group. In the multivariate analysis, intraoperative blood loss of > 275 mL [odds ratio (OR) = 5.32, 95% confidence interval (CI): 1.05-27.0, P = 0.044] and plasma D-dimer levels on POD 5 ≥ 21 μg/mL (OR = 10.1, 95%CI: 2.04-50.1, P = 0.0046) were independent risk factors for VTE after hepatectomy., Conclusion: Monitoring of plasma D-dimer levels after hepatectomy is useful for early diagnosis of VTE and may avoid routine prophylactic anticoagulation in the postoperative period., Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article., (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.